Patents Assigned to Epivax, Inc.
  • Peptides for inducing heterosubtypic influenza T cell responses
    Patent number: 12247053
    Abstract: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infection also are described.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: March 11, 2025
    Assignees: Saint Louis University, EpiVax, Inc.
    Inventors: Daniel F. Hoft, Christopher S. Eickhoff, Annie De Groot
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 12016909
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: June 25, 2024
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • epitopes for T cell-targeted Q fever vaccines
    Patent number: 11690902
    Abstract: Compositions and methods for inducing a protective immune response against Coxiella burnetii, to reduce a subject's risk of developing Q fever.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 4, 2023
    Assignees: The General Hospital Corporation, EpiVax, Inc., Innatoss Laboratories B.V.
    Inventors: Mark C. Poznansky, Ann Elizabeth Sluder, Timothy Alan Brauns, Anne Searls De Groot, Leonard Jeffrey Moise, Anja Garritsen, Anja Scholzen
  • PEPTIDES FOR INDUCING HETEROSUBTYPIC INFLUENZA T CELL RESPONSES
    Publication number: 20210380644
    Abstract: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infection also are described.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 9, 2021
    Applicants: Saint Louis University, EpiVax, Inc.
    Inventors: Daniel F. HOFT, Christopher S. EICKHOFF, Annie DE GROOT
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 11045529
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 11045528
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 11045530
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 11045532
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 10925939
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 23, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 10925940
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 23, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 10925941
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: February 23, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 10925942
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 23, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Peptides for inducing Chagas disease responses
    Patent number: 10821164
    Abstract: The present disclosure relates to vaccine formulations and their use in treating and preventing Chagas Disease.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: November 3, 2020
    Assignees: Saint Louis University, EPIVAX, INC.
    Inventors: Daniel Hoft, Chris Eickhoff, Annie De Groot
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 10751397
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 25, 2020
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF
    Publication number: 20190351036
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 21, 2019
    Applicant: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF
    Publication number: 20190183993
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 20, 2019
    Applicant: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF
    Publication number: 20190183994
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 20, 2019
    Applicant: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Modified H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence
    Patent number: 10286063
    Abstract: The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 14, 2019
    Assignee: EPIVAX, INC.
    Inventors: Anne S De Groot, William D Martin
  • METHODS FOR IMPROVING THE EFFICACY OF VACCINE ANTIGENS
    Publication number: 20190105386
    Abstract: The present technology is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.
    Type: Application
    Filed: November 28, 2018
    Publication date: April 11, 2019
    Applicant: EpiVax, Inc.
    Inventors: Anne S. De Groot, William D. Martin
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 10213496
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: February 26, 2019
    Assignee: EPIVAX, INC.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera